GSK’s vaccines business faced challenges in the third quarter, with lower sales forecasts for vaccines for the year. Sales of the RSV vaccine, Arexvy, dropped by over 70% due to narrower U.S. recommendations. Both Arexvy and the shingles vaccine Shingrix fell below analyst forecasts. It was expected that GSK’s vaccine division would see lower sales this quarter. The company’s once successful vaccines business is now experiencing setbacks, highlighting the impact of changing recommendations on vaccine sales.
Source link
GSK’s RSV vaccine sees major fall in sales
